Christopher van Dyck, MD
Elizabeth Mears and House Jameson Professor of Psychiatry and of Neurology and NeuroscienceCards
About
Research
Overview
Neuroimaging of Alzheimer’s Disease and Brain Aging.
The current research focus of Dr. van Dyck and the Alzheimer’s Disease Research Unit (ADRU) is PET imaging of molecular targets of interest for Alzheimer’s disease across the full spectrum of disease from presymptomatic to symptomatic stages. These targets include the amyloid and tau proteins, glucose metabolism and synaptic vesicle glycoprotein 2A (SV2A) as an index of synaptic density. In particular, our team has led the development of SV2A PET in characterizing synaptic changes in Alzheimer’s disease and their relationships with amyloid and tau pathogenesis, glucose metabolism, and fluid biomarkers of synaptic and axonal integrity. The ability to characterize these changes in vivo has also permitted the study of associations with neuropsychological function. Our latest research is moving to the pre-symptomatic stages of Alzheimer’s disease —to investigate the earliest neurobiological changes, including their longitudinal sequence.
Therapeutic Studies of Alzheimer’s Disease and Brain Aging.
Dr. van Dyck has led or participated in more than 100 clinical trials for Alzheimer’s disease, including the prodromal or preclinical stages. His extensive work in therapeutics culminated in 2023 in the lead authorship of the publication of the first disease-modifying treatment for Alzheimer’s disease (N. Engl. J. Med. 2023). Of particular interest is the intersection of neuroimaging and therapeutics and the use of SV2A PET as an outcome measure for trials of disease-modifying therapies.
Medical Research Interests
Academic Achievements & Community Involvement
Clinical Care
Overview
Clinical Specialties
Fact Sheets
Alzheimer's Disease
Learn More on Yale Medicine
Board Certifications
Geriatric Psychiatry
- Certification Organization
- AB of Psychiatry & Neurology
- Latest Certification Date
- 2013
- Original Certification Date
- 1994
Psychiatry
- Certification Organization
- AB of Psychiatry & Neurology
- Original Certification Date
- 1991
Yale Medicine News
News & Links
Media
- Coronal sections of average parametric images of DVR for (A) 19 Cognitively Normal participants and (B) 34 Alzheimer's Disease participants. Average images are created after co-registration to a common template. The average parametric PET scans are displayed in pseudocolor representing [11C]UCB-J binding to SV2A (DVR) and overlaid on the Montreal Neurological Institute (MNI) template T1 MRI. Lower DVR in Alzheimer's Disease compared to Cognitively Normal participants was apparent in the medial temporal lobe and throughout the cortex and subcortex.
News
- March 20, 2023
Jain Receives AHA Career Development Award
- January 19, 2023Source: Yale Medicine
Lecanemab, the New Alzheimer’s Treatment: 3 Things To Know
- January 09, 2023
Alzheimer's Drug Validated in Yale-led Trial Gets FDA Accelerated Approval
- January 04, 2023Source: YaleNews
Drug Slows Clinical Decline of Patients With Early-stage Alzheimer’s in Yale-led Study